**Supplementary Table 5. Correlations between inflammatory factors and the postoperative inflammatory response**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | **EPCO 1 month** | **EPCO 3 months** | **EPCO 1year** |
|  |  | **r** | **p** | **r** | **p** | **r** | **p** |
| ***Cytokines*** | **IL-1α** | -0.001 | 0.998 | -0.003 | 0.993 | -0.494 | 0.397 |
|  | **IL-1β** | 0.078 | 0.760 | 0.254 | 0.510 | 0.051 | 0.935 |
|  | **IL-1RA** | -0.402 | **0.013\*** | -0.413 | **0.029\*** | 0.368 | 0.542 |
|  | **IL-2** | 0.168 | 0.506 | 0.135 | 0.728 | 0.473 | 0.421 |
|  | **IL-3** | -0.157 | 0.383 | -0.524 | **0.006\*** | 0.272 | 0.180 |
|  | **IL-4** | 0.196 | 0.435 | -0.228 | 0.555 | -0.947 | 0.054 |
|  | **IL-5** | -0.113 | 0.656 | -0.111 | 0.775 | -0.024 | 0.969 |
|  | **IL-6** | -0.110 | 0.663 | 0.128 | 0.742 | -0.099 | 0.875 |
|  | **IL-7** | 0.073 | 0.774 | -0.353 | 0.352 | 0.402 | **0.005\*** |
|  | **IL-9** | 0.190 | 0.451 | -0.309 | 0.419 | 0.668 | 0.218 |
|  | **IL-10** | -0.118 | 0.640 | -0.236 | 0.540 | 0.428 | 0.472 |
|  | **IL-12P40** | -0.049 | 0.848 | 0.377 | 0.317 | -0.111 | 0.859 |
|  | **IL-12P70** | -0.252 | 0.312 | -0.493 | 0.177 | 0.198 | 0.750 |
|  | **IL-13** | 0.206 | 0.412 | -0.339 | 0.372 | 0.176 | 0.777 |
|  | **IL-15** | -0.124 | 0.623 | -0.174 | 0.655 | 0.306 | 0.617 |
|  | **IL-17A** | -0.166 | 0.510 | -0.012 | 0.976 | -0.583 | 0.302 |
|  | **TNFα** | -0.059 | 0.816 | -0.568 | 0.111 | 0.801 | 0.103 |
|  | **TNFβ** | 0.119 | 0.639 | -0.402 | **0.046\*** | -0.468 | 0.427 |
|  | **IFNγ** | -0.010 | 0.968 | -0.493 | 0.177 | -0.701 | 0.187 |
|  | **IFNα2** | 0.020 | 0.937 | -0.335 | 0.378 | 0.862 | 0.060 |
|  | **sCD40L** | 0.003 | 0.989 | -0.184 | 0.635 | 0.537 | 0.351 |
| ***Chemokines*** | **G-CSF** | -0.078 | 0.757 | -0.277 | 0.471 | 0.744 | 0.150 |
|  | **GM-CSF** | 0.369 | 0.132 | -0.282 | 0.463 | -0.583 | 0.303 |
|  | **MCP-1** | 0.146 | 0.564 | 0.052 | 0.895 | 0.788 | 0.114 |
|  | **MCP-3** | 0.213 | 0.395 | -0.126 | 0.747 | 0.249 | 0.686 |
|  | **MIP-1α** | 0.028 | 0.911 | -0.164 | 0.674 | -0.926 | 0.064 |
|  | **MIP-1β** | -0.121 | 0.621 | -0.773 | 0.140 | -0.166 | 0.790 |
|  | **IL-8** | -0.251 | 0.316 | -0.385 | 0.306 | 0.359 | 0.553 |
|  | **IP-10** | -0.272 | 0.275 | -0.079 | 0.839 | 0.605 | 0.280 |
|  | **Fractalkine** | 0.087 | 0.731 | -0.454 | 0.220 | 0.705 | 0.183 |
|  | **MDC** | -0.271 | 0.277 | -0.041 | 0.916 | 0.326 | **0.036\*** |
|  | **Eotaxin** | -0.200 | 0.427 | -0.289 | 0.451 | 0.675 | 0.212 |
|  | **GRO** | -0.113 | 0.656 | -0.345 | 0.364 | 0.854 | 0.066 |
|  | **RANTES** | -0.166 | 0.510 | 0.202 | 0.603 | 0.574 | 0.312 |
| ***Growth factors*** | **EGF** | 0.090 | 0.723 | 0.023 | 0.954 | -0.298 | 0.626 |
|  | **FGF-2** | 0.184 | 0.464 | -0.283 | 0.460 | -0.001 | 0.999 |
|  | **TGF-α** | 0.232 | 0.354 | -0.512 | 0.159 | -0.290 | 0.636 |
|  | **PDGF-AA** | 0.497 | **0.030\*** | 0.647 | **0.009\*** | -0.130 | 0.835 |
|  | **PDGF-AB/BB** | 0.086 | 0.734 | -0.355 | 0.349 | 0.394 | 0.512 |
|  | **Flt-3L** | 0.161 | 0.523 | -0.427 | 0.252 | 0.210 | 0.735 |
|  | **VEGF** | -0.020 | 0.938 | 0.333 | 0.381 | -0.139 | 0.823 |
|  |  |  |

Partial correlation (Spearman) analysis controlling for “age” and “cataract morphology” was conducted.

IL=Interleukin, TNF=Tumor necrosis factor, IFN=Interferon, G-CSF=Granulocyte colony stimulating factor, GM-CSF=Granulocyte macrophage colony-stimulating factor, MCP=Monocyte chemotactic protein, sCD40L=Soluble CD40 ligand, MIP=Macrophage inflammatory protein, IP=Interferon-inducible protein, GRO=Growth-regulated oncogene, RANTES=Regulated upon activation, normal T cell expressed and presumably secreted, EGF=Epidermal growth factor, FGF=Fibroblast growth factor, PDGF=Platelet-derived growth factor, VEGF=Vascular endothelial growth factor.